Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Inflammatory Bowel Diseases

  Free Subscription


04.02.2019

3 Aliment Pharmacol Ther
1 Am J Gastroenterol
2 BMC Gastroenterol
1 Clin Gastroenterol Hepatol
3 Eur J Gastroenterol Hepatol
5 Gastroenterology
4 Inflamm Bowel Dis
5 J Crohns Colitis
2 Lancet Child Adolesc Health
3 PLoS One
2 Scand J Gastroenterol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. GHERSIN I, Khteeb N, Katz LH, Daher S, et al
    Trends in the epidemiology of inflammatory bowel disease among Jewish Israeli adolescents: a population-based study.
    Aliment Pharmacol Ther. 2019 Jan 27. doi: 10.1111/apt.15160.
    PubMed     Text format     Abstract available

  2. DE FRANCISCO R, Castano-Garcia A, Riestra S
    Letter: impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2019;49:477-478.
    PubMed     Text format    

  3. AHMED T, Brown F, Ahmed R, Shah A, et al
    Letter: impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019;49:476-477.
    PubMed     Text format    


    Am J Gastroenterol

  4. BATTAT R, Duijvestein M, Guizzetti L, Choudhary D, et al
    Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Am J Gastroenterol. 2019 Jan 25. doi: 10.14309/ajg.0000000000000111.
    PubMed     Text format     Abstract available


    BMC Gastroenterol

  5. PATEL R, Coulter LL, Rimmer J, Parkes M, et al
    Mitochondrial neurogastrointestinal encephalopathy: a clinicopathological mimic of Crohn's disease.
    BMC Gastroenterol. 2019;19:11.
    PubMed     Text format     Abstract available

  6. TCYMBAREVICH IV, Eloranta JJ, Rossel JB, Obialo N, et al
    The impact of the rs8005161 polymorphism on G protein-coupled receptor GPR65 (TDAG8) pH-associated activation in intestinal inflammation.
    BMC Gastroenterol. 2019;19:2.
    PubMed     Text format     Abstract available


    Clin Gastroenterol Hepatol

  7. GRACIE DJ, Ford AC
    Functional Gastrointestinal Symptoms in Inflammatory Bowel Disease: Rising to the Challenge.
    Clin Gastroenterol Hepatol. 2019;17:572-573.
    PubMed     Text format    


    Eur J Gastroenterol Hepatol

  8. MOLENDIJK I, van der Meulen-de Jong AE, Verspaget HW, Veenendaal RA, et al
    Standardization of mesenchymal stromal cell therapy for perianal fistulizing Crohn's disease.
    Eur J Gastroenterol Hepatol. 2018;30:1148-1154.
    PubMed     Text format     Abstract available

  9. AALTONEN G, Keranen I, Carpelan-Holmstrom M, Lepisto A, et al
    Risk factors for anastomotic recurrence after primary ileocaecal resection in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2018;30:1143-1147.
    PubMed     Text format     Abstract available

  10. BOHN THOMSEN S, Kiszka-Kanowitz M, Theede K, Gluud LL, et al
    Optimized thiopurine therapy before withdrawal of anti-tumour necrosis factor-alpha in patients with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2018;30:1155-1158.
    PubMed     Text format     Abstract available


    Gastroenterology

  11. HANAUER SB, Sandborn WJ, Lichtenstein GR
    Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary.
    Gastroenterology. 2019;156:36-42.
    PubMed     Text format     Abstract available

  12. BORGERINK MMH, Weersma RK, Visschedijk MC
    A Case Report of a Young Adult With Progressive Bloody Diarrhea, Protein-Losing Enteropathy, and Extended Polyposis Coli.
    Gastroenterology. 2019;156:e10-e11.
    PubMed     Text format    

  13. LEHLE AS, Farin HF, Marquardt B, Michels BE, et al
    Intestinal Inflammation and Dysregulated Immunity in Patients With Inherited Caspase-8 Deficiency.
    Gastroenterology. 2019;156:275-278.
    PubMed     Text format    

  14. CROSS R, Ko CW, Singh S
    Mild-to-Moderate Ulcerative Colitis Guideline.
    Gastroenterology. 2019 Jan 23. pii: S0016-5085(19)30097.
    PubMed     Text format    


  15. Mild-to-Moderate Ulcerative Colitis (UC) Clinical Decision Support Tool.
    Gastroenterology. 2019 Jan 23. pii: S0016-5085(19)30099.
    PubMed     Text format    


    Inflamm Bowel Dis

  16. VASUDEVAN A, Gibson PR, Van Langenberg DR
    Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2019 Jan 25. pii: 5300059. doi: 10.1093.
    PubMed     Text format     Abstract available

  17. LEONE D, Gilardi D, Corro BE, Menichetti J, et al
    Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients.
    Inflamm Bowel Dis. 2019 Jan 28. pii: 5303250. doi: 10.1093.
    PubMed     Text format     Abstract available

  18. BYNDLOSS MX, Litvak Y, Baumler AJ
    Microbiota-nourishing Immunity and Its Relevance for Ulcerative Colitis.
    Inflamm Bowel Dis. 2019 Jan 30. pii: 5304210. doi: 10.1093.
    PubMed     Text format    

  19. VELASCO RODRIGUEZ-BELVIS M, Viada Bris JF, Palomino Perez L, Munoz Codoceo RA, et al
    Regain of Response to Adalimumab in a Steroid-Dependent Pediatric Patient With Ulcerative Colitis After Undergoing Selective Granulocyte and Monocyte Apheresis.
    Inflamm Bowel Dis. 2019 Jan 30. pii: 5304206. doi: 10.1093.
    PubMed     Text format    


    J Crohns Colitis

  20. WANG MH, Friton JJ, Raffals LE, Leighton JA, et al
    Novel Genetic Risk Variants Can Predict Anti-TNF Agent Response in Patients With Inflammatory Bowel Disease.
    J Crohns Colitis. 2019 Jan 21. pii: 5299128. doi: 10.1093.
    PubMed     Text format     Abstract available

  21. PAPAMICHAEL K, Juncadella A, Wong D, Rakowsky S, et al
    Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared to standard of care in patients with inflammatory bowel disease.
    J Crohns Colitis. 2019 Jan 21. pii: 5298979. doi: 10.1093.
    PubMed     Text format     Abstract available

  22. LO PRESTI E, Di Mitri R, Mocciaro F, Di Stefano AB, et al
    Characterization of gammadelta T cells in intestinal mucosa from patients with early onset or long standing inflammatory bowel disease and their correlation with clinical status.
    J Crohns Colitis. 2019 Jan 21. pii: 5298961. doi: 10.1093.
    PubMed     Text format     Abstract available

  23. SLUITER RL, van Marrewijk C, de Jong D, Scheffer H, et al
    Genotype-guided thiopurine dosing does not lead to additional costs in patients with inflammatory bowel disease.
    J Crohns Colitis. 2019 Jan 30. pii: 5304472. doi: 10.1093.
    PubMed     Text format     Abstract available

  24. POUILLON L, Rousseau H, Busby-Venner H, De Carvalho Bittencourt M, et al
    Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis.
    J Crohns Colitis. 2019 Jan 29. pii: 5304135. doi: 10.1093.
    PubMed     Text format     Abstract available


    Lancet Child Adolesc Health

  25. WINTZELL V, Svanstrom H, Olen O, Melbye M, et al
    Association between use of azathioprine and risk of acute pancreatitis in children with inflammatory bowel disease: a Swedish-Danish nationwide cohort study.
    Lancet Child Adolesc Health. 2019 Jan 23. pii: S2352-4642(18)30401.
    PubMed     Text format     Abstract available

  26. ALOI M, Cucchiara S
    Acute pancreatitis and azathioprine in paediatric inflammatory bowel disease.
    Lancet Child Adolesc Health. 2019 Jan 23. pii: S2352-4642(19)30019.
    PubMed     Text format    


    PLoS One

  27. SZANTO K, Nyari T, Balint A, Bor R, et al
    Biological therapy and surgery rates in inflammatory bowel diseases - Data analysis of almost 1000 patients from a Hungarian tertiary IBD center.
    PLoS One. 2018;13:e0200824.
    PubMed     Text format     Abstract available

  28. TAJIRI H, Motoya S, Kinjo F, Maemoto A, et al
    Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan.
    PLoS One. 2018;13:e0201956.
    PubMed     Text format     Abstract available

  29. ROTH N, Biedermann L, Fournier N, Butter M, et al
    Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study.
    PLoS One. 2019;14:e0210436.
    PubMed     Text format     Abstract available


    Scand J Gastroenterol

  30. MOHAN LJ, Daly JS, Ryan BM, Ramtoola Z, et al
    The future of nanomedicine in optimising the treatment of inflammatory bowel disease.
    Scand J Gastroenterol. 2019 Jan 24:1-9. doi: 10.1080/00365521.2018.1563805.
    PubMed     Text format     Abstract available

  31. EVERHOV AH, Sachs MC, Malmborg P, Nordenvall C, et al
    Changes in inflammatory bowel disease subtype during follow-up and over time in 44,302 patients.
    Scand J Gastroenterol. 2019 Jan 31:1-9. doi: 10.1080/00365521.2018.1564361.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: